Nové trendy vo farmakoterapii II. (2011) - Jesseniova lekárska ...

JLF UK v Martine, 2011
4. KARISH SB, GAGNON JM. The potential role of
roflumilast: the new phosphodiesterase-4 inhibitor.
Ann Pharmacother 2006; 40: 1096-
104.
5. KOIKE T., NADEEN QUTAB M., TSUCHIDA M.,
TAKEKUBO M., SAITO M., HAYASHI J. Pretreatment
with olprinone hydrochloride,
a phosphodiesterase III inhibitor, attenuates
lipopolysaccharide-induced lung injury via
and anti-inflammatory effect. Pulm Pharmacol
Ther 2008; 21: 161-77.
6. MATSUDA F, SUGAHARA K, SUGITA M, SADO-
HARA T, KIYOTA T, TERASAKI H. Comparative
effect of amrinone, aminophylline and diltiazem
on rat airway smooth muscle. Acta Anaesthesiol
Scand 2000; 44: 763-6.
7. MOKRÁ D, DRGOVÁ A, PULLMANN R st., ČAL-
KOVSKÁ A. Selective phosphodiesterase-3 inhibitor
olprinone alleviates oxidative lung injury
induced by meconium. In: Zborník abstraktov,
XXII. Biochemický zjazd, Martin: JLF
UK, 2010, s. 218.
8. MOKRA D, MOKRY J, CALKOVSKA A. Antiinflammatory
drugs in the treatment of meconium
aspiration syndrome. Acta Med Martiniana
2011; Suppl 1: 13-21.
9. MOKRY J, MOKRA D, NOSALOVA G, BEHAR-
KOVA M, FEHEROVA Z. Influence of selective
inhibitors of phosphodiesterase 3 and 4 on
cough and airway reactivity. J Physiol Pharmacol
2008; 59 (suppl. 6): 473-82.
10. MOKRY J, NOSALOVA G, MOKRA D. Influence
of xanthine derivatives on cough and airway
reactivity in guinea pigs. J Physiol Pharmacol
2009; 60 (Suppl. 6): 87-91.
11. MOKRY J, NOSALOVA G. Evaluation of the
cough reflex and airway reactivity in tolueneand
ovalbumin- induced airway hyperresponsiveness.
J Physiol Pharmacol 2007; 58 (Suppl
5): 419-26.
12. MOKRÝ J. Využitie inhibítorov fosfodiesteráz
v ovplyvnení niektorých patologických stavov
spojených s hyperreaktivitou dýchacích ciest.
Habilitačná práca, JLF UK Martin, 2008, 176 s.
13. RENNARD S., KNOBIL K., RABE K.F., MORRIS
A., SCHACHTER N., LOCANTORE N., CANONI-
CA W.G., ZHU Y., BARNHART F. The efficacy
and safety of cilomilast in COPD. Drugs 2008;
68: 3-57.
14. SUTOVSKA M, FRANOVA S, SUTOVSKY J. The
influence of animal species on the relationship
between ATP-sensitive potassium ion
channels and defense reflexes of the airways.
Bratisl Med J 2009; 110 (5), 269-75.
15. VESTBO J., TAN L., ATKINSON G., WARD J on
behalf of the UK-500,001 Global Study Team.
A controlled trial of 6-weeks` treatment with
a novel inhaled phosphodiesterase type-4 inhibitor
in COPD. Eur Respir J 2009; 33: 1039-
44.
16. WANG Y.J., JIANG Y.L., TANG H.F., ZHAO C.Z.,
CHEN J.Q. Zl-n-91, a selective phosphodiesterase
4 inhibitor, supresses inflammatory response
in a COPD-like rat model. Int Immunopharmacol
2010; 10: 252-8.
17. SPINA D. PDE4 inhibitors: current sttus. Br J
Pharmacol 2008; 155: 308-15.
34